Format

Send to

Choose Destination
J Allergy Clin Immunol. 2015 Dec;136(6):1517-1522. doi: 10.1016/j.jaci.2015.08.037. Epub 2015 Oct 21.

Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: Results of the US Medical Expenditure Panel Survey.

Author information

1
Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Ontario, Canada.
2
School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
3
Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Science, University of Calgary, Calgary, Alberta, Canada.
4
Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: kiltysj@gmail.com.

Abstract

BACKGROUND:

Chronic rhinosinusitis (CRS) is an inflammatory disease that affects 2% to 16% of the US population. Despite its increasing prevalence, there are currently limited data in the literature evaluating the economic burden of this disease.

OBJECTIVE:

This study aimed to determine the direct health care costs of CRS from the perspective of the US government.

METHODS:

A prevalence-based approach was used to estimate cost of illness for CRS from the 2011 Medical Expenditure Panel Survey database by using a 4-part model: (1) an estimated sum of all health care expenditures, (2) an attribution model for disease-specific estimation of expenditures, (3) an estimation based on a propensity score model, and (4) estimated disease-specific expenditure by using a linear regression-based approach. A disease prevalence of 3.5% was used.

RESULTS:

The mean CRS-specific annual expenditure was $5955 (95% CI, $5087-$6823) by using method 1 compared with $5560 (95% CI, $4689-$6431) by using method 2 and $5560 (95% CI, $4653-$6467) by using method 3. The annual expenditure, as estimated by using method 4, was $5589 (95% CI, $4986-$6192). Ambulatory expenses accounted for the largest proportion of expenditures, followed by prescription and in-hospital expenses.

CONCLUSIONS:

This study provided a range of estimates of the direct medical expenditures associated with CRS. We demonstrated that the economic burden attributable to this disease was an estimated $60.2 to $64.5 billion US dollars in 2011, with a wide variation in the total and incremental direct expenditures depending on the type of estimation model used and the prevalence assumed.

KEYWORDS:

Chronic rhinosinusitis; Medical Expenditure Panel Survey; cost; direct medical expenditures; rhinosinusitis treatment

PMID:
26483176
DOI:
10.1016/j.jaci.2015.08.037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center